Anti-BR Recombinant Immunotoxin (DT386-BR(RAGLQFPVG)) (CAT#: BioBet-IT004Z) Datasheet

Target
BR
IT Type
Peptide-based IT
Description
DT386-BR2 is a 47 KDa fusion protein that contains the first 386 residues of DT fused to the antimicrobial peptide BR2 via a rigid peptide linker (AP) 4. BR2 is derived from bufoin IIb (RAGLQFPVG [RLLR] 3), an effective antibacterial peptide with cell penetration and anti-cancer properties. BR2 has only two terminal RLLR repeats and has the ability to penetrate and kill cancer cells without affecting normal cells. In vitro studies have shown that DT386-BR2 is cytotoxic to HeLa (cervical cancer) and MCF-7 (breast cancer) cells, and has almost no toxicity to HEK 293 and HUVEC cells.
Indication
Breast cancer, leukemia, cervical cancer
Classification
Immuntoxin; biobetter
Construction
DT386-BR(RAGLQFPVG)

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop our ADCC/CDC-enhanced antibodies or immutoxins. For commercial partners interested in our therapeutic biobetter product, Creative Biolabs welcomes collaboration.
Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
BR2
Full Name
BR2 peptide
Background
RAGLQFPVGRLLRRLLR
Species Reactivity
Human
Antibody Indication
Breast cancer, leukemia, cervical cancer
Peptide
BR (RAGLQFPVGRLLRRLLR)
Peptide Sequence
RAGLQFPVG
Toxic Moiety
DT386
Organism
Corynebacterium
Family
Diphtheria toxin
Toxic MOA
Diphtheria toxin kills cells by inhibiting eukaryotic protein synthesis, and its mechanism of action has been extensively characterized. This potent toxin inactivates elongation factor (EF-2) required for protein synthesis. Specifically, diphtheria toxin transfers the ADP-ribose moiety of NAD to EF-2, and thus blocks the translational machinery of target cells.

Breast cancer, leukemia, cervical cancer

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK